Zobrazeno 41 - 50
of 201
pro vyhledávání: ''
Autor:
George T. Grossberg
Publikováno v:
Current Therapeutic Research. 64:216-235
Background: Cholinesterase (ChE) inhibitors currently used in the treatment of Alzheimer's disease (AD) are the acetylcholinesterase (AChE)-selective inhibitors, donepezil and galantamine, and the dual AChE and butyrylcholinesterase (BuChE) inhibitor
Autor:
Mei Zhen Zhou, You Jian He, Minoru Yamamoto, Tomoko Kikkawa, Yu Hong Li, Yan Chen, Feng Yi Feng, Gang Cheng, Pin Zhang
Publikováno v:
Current Therapeutic Research. 63:725-735
Background: Chemotherapeutic drugs used to treat cancer may cause nausea and emesis by inducing the release of 5-hydroxytryptamine (5-HT) in the small intestine. Blockage of 5-HT 3 receptors in the small intestine by 5-HT 3 -receptor antagonists migh
Publikováno v:
Current Therapeutic Research. 63:621-633
Background: Many obese patients have comorbidities that worsen their prognoses, particularly if hypercholesterolemia is present. In these patients, dietary restrictions are not sufficient to reduce hypercholesterolemia and lose body weight. Objective
Autor:
Kushida Kazuhiro, Orimo Hajime, Fukunaga Masao, Nakamura Toshitaka, Kaneda Kiyoshi, Yamamoto Kichizo, Morii Hirotoshi, Kishimoto Hideaki, Inoue Tetsuro, Nakashima Mituyoshi, Shiraki Masataka
Publikováno v:
Current Therapeutic Research. 63:606-620
Background: Alendronate, a potent antiresorptive agent, effectively reduces fracture risk. Alendronate increases bone mineral density (BMD) and decreases bone turnover markers to a similar extent in white and Asian people, including Japanese. However
Autor:
Giorgio Giorgi, Elisabetta A. Renzoni, G. Gragnoli, Cheti Puccetti, Signorini Am, Cecilia Fondelli
Publikováno v:
Current Therapeutic Research. 63:411-420
Background: Hyperglycemia increases oxygen-reactive species generation and reduces the protective capabilities of antioxidant defense systems. In patients with type 1 or 2 diabetes mellitus (DM), the increased production of oxygen free radicals may b
Autor:
Shinya Hiramitsu, Seiji Hiramitsu
Publikováno v:
Current Therapeutic Research. 63:388-395
Background: Atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, was introduced in Japan in May 2000 with purportedly potent cholesterol-lowering effects. However, only a handful of studies have assessed its efficacy a
Publikováno v:
Current Therapeutic Research. 62:930-941
Background: The antineoplastic agent ifosfamide is capable of causing renal damage in children. It is not known why children younger than 3 years experience more nephrotoxicity, regardless of the concurrent administration of the synthetic thiol compo
Autor:
Sidney D. Nelson
Publikováno v:
Current Therapeutic Research. 62:885-899
Background: Other than alkylating agents used in cancer chemotherapy, most drugs that cause adverse reactions require metabolism to structures that can react with constituents of our cellular environment to form products that initiate a chain of chem
Autor:
C. Berra, Adriana Branchi, Fulvio Muzio, A. Rovellini, Domenico Sommariva, Adriana Torri, A.M. Fiorenza
Publikováno v:
Current Therapeutic Research. 62:408-415
Background: Some reports suggest that atorvastatin is more effective than other statins in decreasing serum triglyceride (TG) levels in patients with hypercholesterolemia. Objective: The aim of this study is to compare the hypotriglyceridemic activit
Publikováno v:
Current Therapeutic Research. 62:274-278
Background: Smoking in pregnancy is associated with increased perinatal risks, including intrauterine growth retardation, stillbirth, and the sudden infant death syndrome. Reducing maternal smoking using nicotine replacement therapy (NRT) is a possib